BMEA

NASDAQ open

Biomea Fusion

0.55 USD
▼-0.03-5.93%
盘后 0.59 0.00%
2026-11-20
市值
$41.75M
市盈率
—
EPS
-0.31
股息率
—
52 周区间
0.45 – 2.24
成交量
931.68K
Beta
-0.14
目标价
6.17
52W 低 0.4552W 高 2.24
价格走势

公司简介

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for ...

关联新闻